TP53 and cancer: Its effectiveness against cancer has been demonstrated in vitro on a wide panel of cancer cellular models, including OS, cervical carcinoma, acute T-cell lymphoblastic leukemia, hepatocellular carcinoma, breast carcinoma, chronic myeloid leukemia, non-small-cell lung carcinoma, colon and colorectal carcinoma, ovarian carcinoma, alveolar cell carcinoma, where it inhibited protein synthesis and induced nucleolar stress and apoptosis through p53 stabilization [92,93,94].